Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,401
archived clinical trials in
Alzheimer Disease

Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2, 24-Month, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Amyloid-Imaging Positron Emission Tomography (PET) and Safety Study of ACC-001 and QS-21 Adjuvant in Subjects With Mild to Moderate Alzheimer's Disease
Status: Archived
Janssen AI Investigational Site
mi
from
Chapel Hill, NC
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2, 24-Month, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Amyloid-Imaging Positron Emission Tomography (PET) and Safety Study of ACC-001 and QS-21 Adjuvant in Subjects With Mild to Moderate Alzheimer's Disease
Status: Archived
Updated: 1/1/1970
Janssen AI Investigational Site
mi
from
Chapel Hill, NC
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2, 24-Month, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Amyloid-Imaging Positron Emission Tomography (PET) and Safety Study of ACC-001 and QS-21 Adjuvant in Subjects With Mild to Moderate Alzheimer's Disease
Status: Archived
Janssen AI Investigational Site
mi
from
Beachwood, OH
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2, 24-Month, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Amyloid-Imaging Positron Emission Tomography (PET) and Safety Study of ACC-001 and QS-21 Adjuvant in Subjects With Mild to Moderate Alzheimer's Disease
Status: Archived
Updated: 1/1/1970
Janssen AI Investigational Site
mi
from
Beachwood, OH
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2, 24-Month, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Amyloid-Imaging Positron Emission Tomography (PET) and Safety Study of ACC-001 and QS-21 Adjuvant in Subjects With Mild to Moderate Alzheimer's Disease
Status: Archived
Janssen AI Investigational Site
mi
from
Oklahoma City, OK
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2, 24-Month, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Amyloid-Imaging Positron Emission Tomography (PET) and Safety Study of ACC-001 and QS-21 Adjuvant in Subjects With Mild to Moderate Alzheimer's Disease
Status: Archived
Updated: 1/1/1970
Janssen AI Investigational Site
mi
from
Oklahoma City, OK
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Clinical Trial Facility
mi
from
Peoria, AZ
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Peoria, AZ
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Clinical Trial Facility
mi
from
Little Rock, AR
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Little Rock, AR
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Clinical Trial Facility
mi
from
Santa Clara, CA
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Santa Clara, CA
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Clinical Trial Facility
mi
from
Denver, CO
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Denver, CO
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Clinical Trial Facility
mi
from
Celebration, FL
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Celebration, FL
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Clinical Trial Facility
mi
from
Atlanta, GA
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Atlanta, GA
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Clinical Trial Facility
mi
from
Centralia, IL
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Centralia, IL
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Clinical Trial Facility
mi
from
St Louis, MO
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
St Louis, MO
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Clinical Trial Facility
mi
from
West Orange, NJ
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
West Orange, NJ
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Clinical Trial Facility
mi
from
Albany, NY
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Albany, NY
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Clinical Trial Facility
mi
from
Bismarck, ND
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Bismarck, ND
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Clinical Trial Facility
mi
from
Lima, OH
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Lima, OH
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Clinical Trial Facility
mi
from
Ponca City, OK
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Ponca City, OK
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Clinical Trial Facility
mi
from
Medford, OR
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Medford, OR
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Clinical Trial Facility
mi
from
Philadelphia, PA
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Philadelphia, PA
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Clinical Trial Facility
mi
from
Nashville, TN
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Nashville, TN
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Clinical Trial Facility
mi
from
Austin, TX
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Austin, TX
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Clinical Trial Facility
mi
from
Burlington, VT
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Burlington, VT
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Clinical Trial Facility
mi
from
Mountlake Terrace, WA
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Mountlake Terrace, WA
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Clinical Trial Facility
mi
from
Milwaukee, WI
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
A 52-week, 2-period, Multicenter, Randomized, Double-blind, Donepezil-referenced, Placebo-controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Milwaukee, WI
Functional Magnetic Resonance Imaging (fMRI) of Anosognosia in Amnestic Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD)
FMRI of Anosognosia in Amnestic MCI and AD: Focus on Cortical Midline Structures
Status: Archived
William S. Middleton Memorial VA Hospital
mi
from
Madison, WI
Functional Magnetic Resonance Imaging (fMRI) of Anosognosia in Amnestic Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD)
FMRI of Anosognosia in Amnestic MCI and AD: Focus on Cortical Midline Structures
Status: Archived
Updated: 1/1/1970
William S. Middleton Memorial VA Hospital
mi
from
Madison, WI
Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab
A Multicenter, Open-Label, Multiple Dose, Parallel Group Investigation Of The Long-Term Safety, Tolerability, Reactogenicity And Efficacy Of Bapineuzumab Administered Subcutaneously In Subjects With Mild To Moderate Alzheimer Disease
Status: Archived
Strong Memorial Hospital (University of Rochester School of Medicine)
mi
from
Rochester, NY
Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab
A Multicenter, Open-Label, Multiple Dose, Parallel Group Investigation Of The Long-Term Safety, Tolerability, Reactogenicity And Efficacy Of Bapineuzumab Administered Subcutaneously In Subjects With Mild To Moderate Alzheimer Disease
Status: Archived
Updated: 1/1/1970
Strong Memorial Hospital (University of Rochester School of Medicine)
mi
from
Rochester, NY
Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab
A Multicenter, Open-Label, Multiple Dose, Parallel Group Investigation Of The Long-Term Safety, Tolerability, Reactogenicity And Efficacy Of Bapineuzumab Administered Subcutaneously In Subjects With Mild To Moderate Alzheimer Disease
Status: Archived
Pfizer Investigational Site
mi
from
Los Angeles, CA
Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab
A Multicenter, Open-Label, Multiple Dose, Parallel Group Investigation Of The Long-Term Safety, Tolerability, Reactogenicity And Efficacy Of Bapineuzumab Administered Subcutaneously In Subjects With Mild To Moderate Alzheimer Disease
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Los Angeles, CA
Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab
A Multicenter, Open-Label, Multiple Dose, Parallel Group Investigation Of The Long-Term Safety, Tolerability, Reactogenicity And Efficacy Of Bapineuzumab Administered Subcutaneously In Subjects With Mild To Moderate Alzheimer Disease
Status: Archived
Raleigh Regional Cancer Center
mi
from
Beckley, WV
Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab
A Multicenter, Open-Label, Multiple Dose, Parallel Group Investigation Of The Long-Term Safety, Tolerability, Reactogenicity And Efficacy Of Bapineuzumab Administered Subcutaneously In Subjects With Mild To Moderate Alzheimer Disease
Status: Archived
Updated: 1/1/1970
Raleigh Regional Cancer Center
mi
from
Beckley, WV
Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab
A Multicenter, Open-Label, Multiple Dose, Parallel Group Investigation Of The Long-Term Safety, Tolerability, Reactogenicity And Efficacy Of Bapineuzumab Administered Subcutaneously In Subjects With Mild To Moderate Alzheimer Disease
Status: Archived
Pfizer Investigational Site
mi
from
Atlanta, GA
Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab
A Multicenter, Open-Label, Multiple Dose, Parallel Group Investigation Of The Long-Term Safety, Tolerability, Reactogenicity And Efficacy Of Bapineuzumab Administered Subcutaneously In Subjects With Mild To Moderate Alzheimer Disease
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Atlanta, GA
Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab
A Multicenter, Open-Label, Multiple Dose, Parallel Group Investigation Of The Long-Term Safety, Tolerability, Reactogenicity And Efficacy Of Bapineuzumab Administered Subcutaneously In Subjects With Mild To Moderate Alzheimer Disease
Status: Archived
Pfizer Investigational Site
mi
from
Arkansas City, KA
Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab
A Multicenter, Open-Label, Multiple Dose, Parallel Group Investigation Of The Long-Term Safety, Tolerability, Reactogenicity And Efficacy Of Bapineuzumab Administered Subcutaneously In Subjects With Mild To Moderate Alzheimer Disease
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Arkansas City, KA
Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab
A Multicenter, Open-Label, Multiple Dose, Parallel Group Investigation Of The Long-Term Safety, Tolerability, Reactogenicity And Efficacy Of Bapineuzumab Administered Subcutaneously In Subjects With Mild To Moderate Alzheimer Disease
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab
A Multicenter, Open-Label, Multiple Dose, Parallel Group Investigation Of The Long-Term Safety, Tolerability, Reactogenicity And Efficacy Of Bapineuzumab Administered Subcutaneously In Subjects With Mild To Moderate Alzheimer Disease
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab
A Multicenter, Open-Label, Multiple Dose, Parallel Group Investigation Of The Long-Term Safety, Tolerability, Reactogenicity And Efficacy Of Bapineuzumab Administered Subcutaneously In Subjects With Mild To Moderate Alzheimer Disease
Status: Archived
Pfizer Investigational Site
mi
from
Cranston, RI
Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab
A Multicenter, Open-Label, Multiple Dose, Parallel Group Investigation Of The Long-Term Safety, Tolerability, Reactogenicity And Efficacy Of Bapineuzumab Administered Subcutaneously In Subjects With Mild To Moderate Alzheimer Disease
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Cranston, RI
Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab
A Multicenter, Open-Label, Multiple Dose, Parallel Group Investigation Of The Long-Term Safety, Tolerability, Reactogenicity And Efficacy Of Bapineuzumab Administered Subcutaneously In Subjects With Mild To Moderate Alzheimer Disease
Status: Archived
Pfizer Investigational Site
mi
from
Houston, TX
Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab
A Multicenter, Open-Label, Multiple Dose, Parallel Group Investigation Of The Long-Term Safety, Tolerability, Reactogenicity And Efficacy Of Bapineuzumab Administered Subcutaneously In Subjects With Mild To Moderate Alzheimer Disease
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Houston, TX
Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab
A Multicenter, Open-Label, Multiple Dose, Parallel Group Investigation Of The Long-Term Safety, Tolerability, Reactogenicity And Efficacy Of Bapineuzumab Administered Subcutaneously In Subjects With Mild To Moderate Alzheimer Disease
Status: Archived
Pfizer Investigational Site
mi
from
Burlington, VT
Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab
A Multicenter, Open-Label, Multiple Dose, Parallel Group Investigation Of The Long-Term Safety, Tolerability, Reactogenicity And Efficacy Of Bapineuzumab Administered Subcutaneously In Subjects With Mild To Moderate Alzheimer Disease
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Burlington, VT
Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab
A Multicenter, Open-Label, Multiple Dose, Parallel Group Investigation Of The Long-Term Safety, Tolerability, Reactogenicity And Efficacy Of Bapineuzumab Administered Subcutaneously In Subjects With Mild To Moderate Alzheimer Disease
Status: Archived
Pfizer Investigational Site
mi
from
Madison, WI
Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab
A Multicenter, Open-Label, Multiple Dose, Parallel Group Investigation Of The Long-Term Safety, Tolerability, Reactogenicity And Efficacy Of Bapineuzumab Administered Subcutaneously In Subjects With Mild To Moderate Alzheimer Disease
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Madison, WI
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type
A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-Center Study Comparing the Effects of Rivastigmine Patch 15 cm2 vs. Rivastigmine Patch 5 cm2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION).
Status: Archived
Clinical Research Advantage/Neuro. Physicians of Arizona, Inc
mi
from
Gilbert, AZ
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type
A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-Center Study Comparing the Effects of Rivastigmine Patch 15 cm2 vs. Rivastigmine Patch 5 cm2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION).
Status: Archived
Updated: 1/1/1970
Clinical Research Advantage/Neuro. Physicians of Arizona, Inc
mi
from
Gilbert, AZ
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type
A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-Center Study Comparing the Effects of Rivastigmine Patch 15 cm2 vs. Rivastigmine Patch 5 cm2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION).
Status: Archived
Northwest Neuro Specialist
mi
from
Tucson, AZ
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type
A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-Center Study Comparing the Effects of Rivastigmine Patch 15 cm2 vs. Rivastigmine Patch 5 cm2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION).
Status: Archived
Updated: 1/1/1970
Northwest Neuro Specialist
mi
from
Tucson, AZ
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type
A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-Center Study Comparing the Effects of Rivastigmine Patch 15 cm2 vs. Rivastigmine Patch 5 cm2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION).
Status: Archived
IHS Research Center Incorporated
mi
from
Conway, AR
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type
A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-Center Study Comparing the Effects of Rivastigmine Patch 15 cm2 vs. Rivastigmine Patch 5 cm2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION).
Status: Archived
Updated: 1/1/1970
IHS Research Center Incorporated
mi
from
Conway, AR
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type
A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-Center Study Comparing the Effects of Rivastigmine Patch 15 cm2 vs. Rivastigmine Patch 5 cm2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION).
Status: Archived
The Research & Education Inst. of Alta Bates Summit Med. Group
mi
from
Berkeley, CA
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type
A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-Center Study Comparing the Effects of Rivastigmine Patch 15 cm2 vs. Rivastigmine Patch 5 cm2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION).
Status: Archived
Updated: 1/1/1970
The Research & Education Inst. of Alta Bates Summit Med. Group
mi
from
Berkeley, CA
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type
A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-Center Study Comparing the Effects of Rivastigmine Patch 15 cm2 vs. Rivastigmine Patch 5 cm2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION).
Status: Archived
ATP Clinical Research, Inc.
mi
from
Costa Mesa, CA
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type
A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-Center Study Comparing the Effects of Rivastigmine Patch 15 cm2 vs. Rivastigmine Patch 5 cm2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION).
Status: Archived
Updated: 1/1/1970
ATP Clinical Research, Inc.
mi
from
Costa Mesa, CA
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type
A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-Center Study Comparing the Effects of Rivastigmine Patch 15 cm2 vs. Rivastigmine Patch 5 cm2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION).
Status: Archived
Margolin Brain Institute
mi
from
Fresno, CA
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type
A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-Center Study Comparing the Effects of Rivastigmine Patch 15 cm2 vs. Rivastigmine Patch 5 cm2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION).
Status: Archived
Updated: 1/1/1970
Margolin Brain Institute
mi
from
Fresno, CA
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type
A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-Center Study Comparing the Effects of Rivastigmine Patch 15 cm2 vs. Rivastigmine Patch 5 cm2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION).
Status: Archived
Collaborative Neuroscience Network
mi
from
Garden Grove, CA
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type
A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-Center Study Comparing the Effects of Rivastigmine Patch 15 cm2 vs. Rivastigmine Patch 5 cm2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION).
Status: Archived
Updated: 1/1/1970
Collaborative Neuroscience Network
mi
from
Garden Grove, CA
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type
A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-Center Study Comparing the Effects of Rivastigmine Patch 15 cm2 vs. Rivastigmine Patch 5 cm2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION).
Status: Archived
Neurology Center of N.Orange County
mi
from
La Habra, CA
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type
A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-Center Study Comparing the Effects of Rivastigmine Patch 15 cm2 vs. Rivastigmine Patch 5 cm2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION).
Status: Archived
Updated: 1/1/1970
Neurology Center of N.Orange County
mi
from
La Habra, CA
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type
A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-Center Study Comparing the Effects of Rivastigmine Patch 15 cm2 vs. Rivastigmine Patch 5 cm2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION).
Status: Archived
Los Angeles County-USC Medical Center
mi
from
Los Angeles, CA
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type
A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-Center Study Comparing the Effects of Rivastigmine Patch 15 cm2 vs. Rivastigmine Patch 5 cm2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION).
Status: Archived
Updated: 1/1/1970
Los Angeles County-USC Medical Center
mi
from
Los Angeles, CA
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type
A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-Center Study Comparing the Effects of Rivastigmine Patch 15 cm2 vs. Rivastigmine Patch 5 cm2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION).
Status: Archived
The Neurology Center
mi
from
Oceanside, CA
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type
A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-Center Study Comparing the Effects of Rivastigmine Patch 15 cm2 vs. Rivastigmine Patch 5 cm2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION).
Status: Archived
Updated: 1/1/1970
The Neurology Center
mi
from
Oceanside, CA
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type
A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-Center Study Comparing the Effects of Rivastigmine Patch 15 cm2 vs. Rivastigmine Patch 5 cm2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION).
Status: Archived
The Center for Memory and Aging
mi
from
Poway, CA
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type
A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-Center Study Comparing the Effects of Rivastigmine Patch 15 cm2 vs. Rivastigmine Patch 5 cm2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION).
Status: Archived
Updated: 1/1/1970
The Center for Memory and Aging
mi
from
Poway, CA
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type
A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-Center Study Comparing the Effects of Rivastigmine Patch 15 cm2 vs. Rivastigmine Patch 5 cm2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION).
Status: Archived
Anderson Clinical Research
mi
from
San Bernardino, CA
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type
A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-Center Study Comparing the Effects of Rivastigmine Patch 15 cm2 vs. Rivastigmine Patch 5 cm2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION).
Status: Archived
Updated: 1/1/1970
Anderson Clinical Research
mi
from
San Bernardino, CA
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type
A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-Center Study Comparing the Effects of Rivastigmine Patch 15 cm2 vs. Rivastigmine Patch 5 cm2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION).
Status: Archived
San Francisco Clinical Research Center
mi
from
San Francisco, CA
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type
A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-Center Study Comparing the Effects of Rivastigmine Patch 15 cm2 vs. Rivastigmine Patch 5 cm2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION).
Status: Archived
Updated: 1/1/1970
San Francisco Clinical Research Center
mi
from
San Francisco, CA
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type
A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-Center Study Comparing the Effects of Rivastigmine Patch 15 cm2 vs. Rivastigmine Patch 5 cm2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION).
Status: Archived
Neuropsychiatric Research Center of Orange County
mi
from
Santa Ana, CA
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type
A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-Center Study Comparing the Effects of Rivastigmine Patch 15 cm2 vs. Rivastigmine Patch 5 cm2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION).
Status: Archived
Updated: 1/1/1970
Neuropsychiatric Research Center of Orange County
mi
from
Santa Ana, CA
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type
A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-Center Study Comparing the Effects of Rivastigmine Patch 15 cm2 vs. Rivastigmine Patch 5 cm2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION).
Status: Archived
California Neuroscience Research Medical Group, Inc.
mi
from
San Fernando Valley, CA
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type
A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-Center Study Comparing the Effects of Rivastigmine Patch 15 cm2 vs. Rivastigmine Patch 5 cm2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION).
Status: Archived
Updated: 1/1/1970
California Neuroscience Research Medical Group, Inc.
mi
from
San Fernando Valley, CA
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type
A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-Center Study Comparing the Effects of Rivastigmine Patch 15 cm2 vs. Rivastigmine Patch 5 cm2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION).
Status: Archived
Viking Clinical Research
mi
from
Temecula, CA
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type
A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-Center Study Comparing the Effects of Rivastigmine Patch 15 cm2 vs. Rivastigmine Patch 5 cm2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION).
Status: Archived
Updated: 1/1/1970
Viking Clinical Research
mi
from
Temecula, CA